贝达药业：拟发行H股股票并在香港联交所上市

Core Viewpoint - The company, Betta Pharmaceuticals (300558), announced plans to issue overseas listed shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange [1] Group 1 - The company received approval from the National Medical Products Administration (NMPA) for its clinical trial application for the drug MCLA-129 in combination with Enasidenib hydrochloride capsules [1]